Artificial Intelligence and Smart Wearable Technologies for Early Detection of Acute Heart Failure
NCT ID: NCT05591443
Last Updated: 2022-10-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
120 participants
OBSERVATIONAL
2023-05-31
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
For these reasons, one of the major unmet needs is the identification of patients with a negative trajectory of Heart Failure. Accordingly, early identification of Heart Failure worsening is mandatory to improve patient condition and reduce Heart Failure costs, which are mainly associated with hospitalizations.
Our main goal through this project is to create clinical tool for detection of early signs of chronic heart failure (CHF) worsening that will allow timely therapeutic intervention. This timely manner intervention can lead to a much better outcome for the patient, possibly reducing the need for hospitalization or lower the number of hospitalization days.
The aim of this project is to develop clinical decision tool based on artificial intelligence (AI) algorithms to early detect the signs of exacerbation of chronic heart failure and predict the risk of its progression, by integrating high quality medical data obtained through a wearable device (L.I.F.E. Italia Srl's "wearable clinic" - a vest with accessories, which is a TRL 9 medical grade sensorized garment, already available on the market). Specifically, the focus will be on the early detection of CHF worsening in patients who have already been diagnosed with CHF.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices
NCT06909682
Detecting EARLY Heart Failure in Greater Manchester
NCT05955456
Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation
NCT06555757
Point of Care Artificial Intelligence Tool for Heart Failure Diagnosis
NCT04601415
Artificial Intelligence Versus Sonographer Echocardiogram Analysis and Reporting in Patients With Heart Failure
NCT07021599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Heart failure patients
Patients with CHF will be considered for inclusion in the study based on their verified medical record, indicating that they are diagnosed with CHF and are using guideline-directed medical therapy (GDMT). Diagnostic criteria, as laid out in the latest 2021 European Society of Cardiology (ESC) guidelines for the diagnosis and management of chronic and acute heart failure, will be followed.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* left ventricular ejection fraction (LVEF) ≤40%. LVEF values will be obtained by determining the reduced LV systolic function, by transthoracic echocardiographic assessment as recommended by European Association of Cardiovascular Imaging (EACVI) and American Society of Echocardiography position paper.
* NYHA functional classes II-III).
Exclusion Criteria
* Candidates for left-ventricular assist device (LVAD) or heart transplant, as per latest definition of Heart Failure Association of the ESC.
* Recent acute coronary syndrome within 1-year prior to the date of potential enrollment,
* Indirect echocardiographic evidence of significantly elevated pulmonary pressures
* Clinically relevant pulmonary hypertension
* non-adherence to optimal medical treatment for CHF
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centro Cardiologico Monzino
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Piergiuseppe Agostoni
Professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
weHeartClinic
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.